MX2009004718A - Antagonistas de receptor de alk1 y ligando y sus usos. - Google Patents

Antagonistas de receptor de alk1 y ligando y sus usos.

Info

Publication number
MX2009004718A
MX2009004718A MX2009004718A MX2009004718A MX2009004718A MX 2009004718 A MX2009004718 A MX 2009004718A MX 2009004718 A MX2009004718 A MX 2009004718A MX 2009004718 A MX2009004718 A MX 2009004718A MX 2009004718 A MX2009004718 A MX 2009004718A
Authority
MX
Mexico
Prior art keywords
ligand
alkl
polypeptide
ligand antagonists
ligands
Prior art date
Application number
MX2009004718A
Other languages
English (en)
Spanish (es)
Inventor
John Knopf
Jasbir Seehra
Asya Grinberg
Ravindra Kumar
Robert Scott Pearsall
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MX2009004718A publication Critical patent/MX2009004718A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
MX2009004718A 2006-11-02 2007-11-02 Antagonistas de receptor de alk1 y ligando y sus usos. MX2009004718A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85659206P 2006-11-02 2006-11-02
PCT/US2007/023217 WO2008057461A2 (en) 2006-11-02 2007-11-02 Alk1 receptor and ligand antagonists and uses thereof

Publications (1)

Publication Number Publication Date
MX2009004718A true MX2009004718A (es) 2009-06-19

Family

ID=39365087

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004718A MX2009004718A (es) 2006-11-02 2007-11-02 Antagonistas de receptor de alk1 y ligando y sus usos.

Country Status (14)

Country Link
US (4) US8455428B2 (https=)
EP (2) EP3181580A1 (https=)
JP (5) JP2010508816A (https=)
KR (3) KR20150008889A (https=)
CN (2) CN111518218A (https=)
AU (1) AU2007317926A1 (https=)
BR (1) BRPI0717964A2 (https=)
CA (1) CA2668411C (https=)
DK (1) DK2087001T3 (https=)
ES (1) ES2612755T3 (https=)
IL (2) IL198522A (https=)
MX (1) MX2009004718A (https=)
RU (2) RU2559532C2 (https=)
WO (1) WO2008057461A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8764725B2 (en) 2004-02-09 2014-07-01 Covidien Lp Directional anchoring mechanism, method and applications thereof
WO2006091930A2 (en) * 2005-02-24 2006-08-31 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
CN111518218A (zh) 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) * 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
KR20100090683A (ko) * 2007-11-09 2010-08-16 제넨테크, 인크. 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법
US7855564B2 (en) * 2008-02-14 2010-12-21 Delaware Capital Formation, Inc. Acoustic wave device physical parameter sensor
JP5719766B2 (ja) * 2008-05-02 2015-05-20 アクセルロン ファーマ， インコーポレイテッド 血管新生および周皮細胞組成物を調節するための方法および組成物
CA2724525A1 (en) * 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
WO2010126169A1 (ja) * 2009-04-30 2010-11-04 協和発酵キリン株式会社 Alk1阻害剤を有効成分とする血管障害を抑制するための医薬組成物
WO2011056494A1 (en) * 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
JP6250533B2 (ja) * 2011-04-20 2017-12-20 アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． エンドグリンポリペプチドおよびその使用
KR101421171B1 (ko) * 2011-08-31 2014-07-22 재단법인 제이씨비 공동생물과학연구소 인간 골형성 단백질 수용체 1ａ의 세포외 도메인을 유효성분으로 포함하는 피부 상태 개선용 조성물
WO2013116781A1 (en) * 2012-02-02 2013-08-08 Acceleron Pharma Inc. Alk1 antagonists and their uses in treating renal cell carcinoma
EP3851118A1 (en) 2013-10-25 2021-07-21 Acceleron Pharma Inc. Endoglin peptides to treat fibrotic diseases
WO2015147908A1 (en) * 2014-03-28 2015-10-01 Acceleron Pharma, Inc. Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer
GB201412290D0 (en) * 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
US10358476B2 (en) 2015-04-06 2019-07-23 Acceleron Pharma Inc. Single arm type I and type II receptor fusion proteins and uses thereof
MA41920B1 (fr) * 2015-04-06 2021-05-31 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
EP3303387A2 (en) 2015-06-05 2018-04-11 Novartis AG Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
CN105254764A (zh) * 2015-08-27 2016-01-20 上海康岱生物医药技术有限公司 ACVR1-Fc融合蛋白及其制法和用途
US20210403549A1 (en) * 2017-05-17 2021-12-30 Yale University Compounds and compositions that inhibit or prevent lipoprotein entry into the endothelium
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1992015602A1 (en) 1991-02-28 1992-09-17 Dana-Farber Cancer Institute, Inc. Cancer diagnosis and therapy
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
WO1994010187A1 (en) 1992-10-30 1994-05-11 Hsc Research And Development Limited Partnership COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b)
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
CA2149441C (en) 1992-11-17 2004-03-02 Kohei Miyazono Activin receptor-like kinases, proteins having serine threonine kinase domains and their use
EP0690871A4 (en) 1993-01-12 1999-10-20 Univ Johns Hopkins Med GROWTH DIFFERENTIATION FACTOR-5
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229557A1 (en) 1995-08-14 1997-02-27 Creative Biomolecules, Inc. Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
US6190660B1 (en) 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
JP4318752B2 (ja) 1996-05-31 2009-08-26 ヘルス・リサーチ・インコーポレーテッド 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
EP0998561A4 (en) 1997-07-15 2004-08-18 Immunex Corp RECEPTOR DES TRAIL PROTEIN
AU3092899A (en) 1998-03-13 1999-09-27 Ludwig Institute For Cancer Research Alk-1 responds to tgf-beta and signals through smad-1 and smad-5
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US20030012792A1 (en) 1998-05-22 2003-01-16 Holaday John W. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
JP2003509011A (ja) * 1999-06-03 2003-03-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 脈管形成タンパク質およびそれらの使用
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
US7077836B2 (en) 2000-07-21 2006-07-18 Vein Rx, Inc. Methods and apparatus for sclerosing the wall of a varicose vein
EP1392333A2 (en) 2000-08-03 2004-03-03 The University of Utah Research Foundation Manipulation of arterial-venous identity
DE10043481A1 (de) 2000-09-04 2002-04-11 Vectron Therapeutics Ag Imt Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
BR0116452A (pt) 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
KR100996226B1 (ko) 2001-10-31 2010-11-24 유니버시티 오브 노스 텍사스 헬스 사이언스 센터 뼈 형태발생 단백질(ｂｍｐ), ｂｍｐ 수용체 및 ｂｍｐ결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
WO2003064628A2 (en) 2002-02-01 2003-08-07 Curagen Corporation Novel proteins and nucleic acids encoding same
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
WO2003093293A2 (en) 2002-04-29 2003-11-13 Saint Louis University Peptide antagonists of tgf-beta family members and therapeutic uses thereof
AU2003247828B2 (en) 2002-06-27 2010-05-20 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
AU2003287444A1 (en) 2002-10-31 2004-05-25 The General Hospital Corporation Repairing or replacing tissues or organs
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
WO2005044849A2 (en) 2003-08-05 2005-05-19 Eli Lilly And Company Lp mammalian proteins; related reagents
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
EP1721257A2 (en) 2004-01-27 2006-11-15 Compugen Ltd. Differential expression of markers in ovarian cancer
EP1740609A2 (en) 2004-04-27 2007-01-10 Research Development Foundation Antagonism of tgf-beta superfamily receptor signaling
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
JP2008507288A (ja) * 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
WO2006091930A2 (en) * 2005-02-24 2006-08-31 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
EP1861425B1 (en) * 2005-03-10 2012-05-16 Morphotek, Inc. Anti-mesothelin antibodies
NZ566774A (en) * 2005-09-07 2011-11-25 Pfizer Human monoclonal antibodies to activin receptor-like kinase-1
JP2009534035A (ja) 2006-04-21 2009-09-24 ワイス 細胞系のハイスループットスクリーニング方法
WO2007143023A1 (en) 2006-05-31 2007-12-13 Beth Israel Deaconess Medical Center Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
CN111518218A (zh) * 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
KR20100090683A (ko) 2007-11-09 2010-08-16 제넨테크, 인크. 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법
JP5719766B2 (ja) 2008-05-02 2015-05-20 アクセルロン ファーマ， インコーポレイテッド 血管新生および周皮細胞組成物を調節するための方法および組成物
CA2724525A1 (en) 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
EP2364371A4 (en) 2008-11-24 2012-05-02 Univ Loma Linda BIOMARKER FOR DETECTING HEADS AND HALSTUMORS
WO2010128158A1 (en) 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders
AU2012212047A1 (en) 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
WO2013116781A1 (en) 2012-02-02 2013-08-08 Acceleron Pharma Inc. Alk1 antagonists and their uses in treating renal cell carcinoma
US20140193425A1 (en) 2012-10-05 2014-07-10 Acceleron Pharma, Inc. Treatment of cancer with alk1 antagonists
WO2015147908A1 (en) 2014-03-28 2015-10-01 Acceleron Pharma, Inc. Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer

Also Published As

Publication number Publication date
WO2008057461A2 (en) 2008-05-15
RU2559532C2 (ru) 2015-08-10
IL198522A0 (en) 2011-08-01
KR20170012582A (ko) 2017-02-02
JP6348448B2 (ja) 2018-06-27
JP2020150955A (ja) 2020-09-24
DK2087001T3 (en) 2017-02-06
CN101652387A (zh) 2010-02-17
IL198522A (en) 2017-06-29
RU2009120695A (ru) 2010-12-10
US20130344067A1 (en) 2013-12-26
CA2668411A1 (en) 2008-05-15
ES2612755T3 (es) 2017-05-18
KR20150008889A (ko) 2015-01-23
CN111518218A (zh) 2020-08-11
CA2668411C (en) 2020-02-25
JP2018127471A (ja) 2018-08-16
US12144860B2 (en) 2024-11-19
AU2007317926A1 (en) 2008-05-15
JP2010508816A (ja) 2010-03-25
EP2087001B1 (en) 2016-10-26
IL253035A0 (en) 2017-08-31
BRPI0717964A2 (pt) 2013-12-17
US20220296708A1 (en) 2022-09-22
RU2013134324A (ru) 2015-01-27
JP2015143269A (ja) 2015-08-06
WO2008057461A3 (en) 2009-02-26
US20170354731A1 (en) 2017-12-14
KR101581961B1 (ko) 2016-01-04
KR20090085662A (ko) 2009-08-07
US8455428B2 (en) 2013-06-04
US20080175844A1 (en) 2008-07-24
EP2087001A2 (en) 2009-08-12
JP2013199496A (ja) 2013-10-03
EP3181580A1 (en) 2017-06-21

Similar Documents

Publication Publication Date Title
MX2009004718A (es) Antagonistas de receptor de alk1 y ligando y sus usos.
WO2009134428A3 (en) Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
MX2010005031A (es) Anticuerpos de axl.
WO2009139891A3 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
MY185200A (en) Anti-cmet antibody
ATE389404T1 (de) Kappa-opioid-rezeptor-liganden
WO2009142732A3 (en) Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
MX2014009277A (es) Antagonistas alk1 y sus usos en el tratamiento de carcinoma de celula renal.
GB0724532D0 (en) Trail variants for treating cancer
MX2009013269A (es) Inhibidores de receptor de cinasas de tirosina y metodos de uso de los mismos.
SI2094690T1 (sl) Derivati 2-aza-biciklo(3.1.0)heksana kot antagonisti receptorja za oreksin
YU80903A (sh) Antitela vla-1
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
EA200701853A1 (ru) Производные циклопентапиридина и тетрагидрохинолина
MX2012008222A (es) Inhibidores de cinasa de y tirosina receptora (rtk) y metodos de uso de las mismas.
WO2010116282A8 (en) 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
EP2275115A3 (en) Inhibition of stress-induced ligand-dependent EGFR activation
MX2010000997A (es) Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b).
WO2011127388A3 (en) Inverse agonists and neutral antagonists for the tsh receptor
MX2010003757A (es) Composiciones que comprenden multimeros optimizados de her1 y her3 y sus metodos de uso.
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
SI2001456T1 (sl) Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni
WO2011116396A3 (en) Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
UA94213C2 (ru) Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
AU2014200003B2 (en) ALK1 receptor and ligand antagonists and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration